MRK vs MXCT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
MaxCyte (MXCT) exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating severe financial deterioration. While the company maintains a strong liquidity cushion with a Current Ratio of 8.30 and low debt, these are offset by a massive profit margin of -135.14% and declining year-over-year revenue growth of -16%. Despite a significant gap between the current price ($0.88) and analyst target prices ($4.05), the deterministic data suggests a high-risk profile characterized by a catastrophic 5-year price decline of 94.8%.
Compare Another Pair
Related Comparisons
MRK vs MXCT: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and MaxCyte, Inc. (MXCT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.